Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

Damaskos C, Psilopatis I, Garmpi A, Dimitroulis D, Nikolettos K, Vrettou K, Sarantis P, Koustas E, Kouraklis G, Antoniou EA, Karamouzis MV, Nikolettos N, Tsikouras P, Marinos G, Kontomanolis E, Kontzoglou K, Garmpis N (2024)

Publication Type: Journal article

Publication year: 2024


Book Volume: 16

Article Number: 209

Journal Issue: 1

DOI: 10.3390/cancers16010209


Background/Aim: Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer. Materials and Methods: A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients. Results: Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer. Conclusions: High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.

Authors with CRIS profile

Involved external institutions

How to cite


Damaskos, C., Psilopatis, I., Garmpi, A., Dimitroulis, D., Nikolettos, K., Vrettou, K.,... Garmpis, N. (2024). Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer. Cancers, 16(1). https://doi.org/10.3390/cancers16010209


Damaskos, Christos, et al. "Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer." Cancers 16.1 (2024).

BibTeX: Download